02681nam 2200589 a 450 991096779720332120251116221052.01-61668-478-X(CKB)2560000000068770(EBL)3019875(SSID)ssj0000415799(PQKBManifestationID)12173982(PQKBTitleCode)TC0000415799(PQKBWorkID)10416286(PQKB)11606005(MiAaPQ)EBC3019875(Au-PeEL)EBL3019875(CaPaEBR)ebr10674883(OCoLC)923662021(BIP)29020753(EXLCZ)99256000000006877020100122d2010 uy 0engur|n|---|||||txtccrDevelopment of new MDR-tuberculosis drugs /Jarmila Vinšová and Martin Krátký1st ed.New York Nova Science Publishers/Nova Biomedicalc20101 online resource (112 p.)Pharmacology-research, safety testing and regulationDescription based upon print version of record.1-61668-233-7 Includes bibliographical references and index.Resistance to commonly used drugs, mechanism of the action -- Research of novel MDR potential drugs.The emergence of resistance to anti-tuberculosis drugs, particularly of MDR-TB and newly XDR-TB, has become a major public health problem. The current treatment regiment has several disadvantages, i.e. long treatment period (DOTS takes minimum 6 months) during which tubercle bacilli mutant become resistant to one or more drugs; side effects of the used drugs; co-infection of HIV/AIDS. The emergence of MDR-TB has made many currently available anti-TB drugs ineffective. Sleeping latent forms of mutant bacilli resistant against common anti-TB drugs pose the risk of epidemic for the new generation. This book outlines the recent advances in the development of new multi-drug-resistant tuberculosis (MDR-TB) drugs.Pharmacology-research, safety testing, and regulation series.Antitubercular agentsMultidrug-resistant tuberculosisChemotherapyAntitubercular agents.Multidrug-resistant tuberculosisChemotherapy.615.5/8Vinšová Jarmila1868138Krátký Martin1960-1868139MiAaPQMiAaPQMiAaPQBOOK9910967797203321Development of new MDR-tuberculosis drugs4475982UNINA